-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist
Pathology—and pathologic staging in particular—can be improved through multidisciplinary efforts.
-
Quality of Life After VATS and SABR for Early-stage Lung Cancer: The Lilac Study
SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks.
-
Early Palliative Care: A European Perspective
The benefits of early palliative care have been proven. Could negative connotations of palliative care be impeding its adoption?
-
Valuable Intersections: Maximizing Career Opportunities Arising From The Relationship Between Academia and Industry
For Dr. Jean-Charles Soria, the opportunity to make science actionable and increase its impact drove his decision to work in industry.
-
IASLC Releases Position Statement on Air Pollution on Earth Day
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer.
-
In Brief for April 27, 2022
Dr. Jhanelle Gray takes the reins as chair of the SWOG Lung Cancer Committee. Keep reading for more about this and other moves in thoracic oncology.
-
IASLC’s Global Reach a Strength on the Road to a Cure for Lung Cancer
In her first letter to ICLN readers, new CEO Karen Kelly discusses keys to achieving the association’s mission.
-
Tumor Growth Rate as a Guide for Precision Lung Cancer Therapy
The speed at which a tumor progresses may prove to be a useful tool in therapeutic decision-making.
-
Patient Perspective: The Promise of Personalized Medicine
Growing treatment options for patients with late-stage lung cancer bring hope—and challenges.
-
Cancer Misinformation: Its Impact on Patients and Mitigation Strategies
Inaccurate health information can have grave consequences, but there are techniques providers can use to combat it.